Convergence Pharma in Cambridge England issued a press release today that pertains to early trial success in calcium channel pain blocking:
Convergence is also in early stage trials for a sodium channel blocker - so the above early promise with calcium channels is potentially indirectly good news for the prospects of their early stage trials with sodium channel blockers.
I really wonder if the sodium blocker would work with our issues. All of this is amazing news. Good luck to all the researchers.
Here's the latest on the NaV 1.7 sodium channel blocker candidate by Convergence:
The NaV 1.7 sodium channel is suspected as the main culprit for erythromelalgia symptoms.